SAB Biotherapeutics Inc (SABS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $266.66M
Last updated: Nov 17, 2026 at 11:05 AM ET
SAB Biotherapeutics Inc (SABS) Competitors
The companies most similar to SAB Biotherapeutics are Palisade Bio (PALI), Precision BioSciences (DTIL) and Cartesian Therapeutics (RNAC). By market cap, SAB Biotherapeutics ranks 5th of the 13 companies on this page; Sana Biotechnology (SANA) is the largest at $605.26M.
Peer Comparison
SABS's revenue growth of -62.4% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics (SABS) | $266.66M | N/A | N/A | 0.0% | N/A | -62.4% | 0.00% |
| Palisade Bio Inc (PALI) | $201.01M | N/A | 436.8x | 0.0% | N/A | 0.0% | 0.00% |
| Precision BioSciences Inc (DTIL) | $288.76M | N/A | 4.4x | -85.6% | -38.3% | 37272.0% | 0.00% |
| Cartesian Therapeutics Inc. (RNAC) | $193.69M | N/A | 179.8x | 0.0% | 147.2% | -92.9% | 0.00% |
| Q32 Bio Inc (QTTB) | $260.64M | 2.5x | 5.2x | 60.0% | N/A | 0.0% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Sana Biotechnology Inc (SANA) | $605.26M | N/A | N/A | 0.0% | -46.8% | 0.0% | 0.00% |
| Sutro Biopharma (STRO) | $163.03M | N/A | 3.4x | 0.0% | N/A | -6.1% | 0.00% |
| Upstream Bio, Inc. (UPB) | $152.38M | N/A | 41.0x | 0.0% | N/A | -42.2% | 0.00% |
| Greenwich Lifesciences Inc (GLSI) | $219.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Shattuck Labs Inc (STTK) | $473.57M | N/A | N/A | 0.0% | N/A | -66.6% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Atrium Therapeutics, Inc. Common Stock (RNA) | $162.00M | N/A | 3.3x | -180.9% | -44.5% | 24.2% | 0.00% |
| Peer median | $210.15M | 2.5x | 4.8x | 0.0% | -38.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to SAB Biotherapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Palisade Bio Inc (PALI) | Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. | PALI competitors |
| Precision BioSciences Inc (DTIL) | Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. | DTIL competitors |
| Cartesian Therapeutics Inc. (RNAC) | Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs... | RNAC competitors |
| Q32 Bio Inc (QTTB) | Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune... | QTTB competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Sana Biotechnology Inc (SANA) | Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington. | SANA competitors |
| Sutro Biopharma (STRO) | Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. | STRO competitors |
| Upstream Bio, Inc. (UPB) | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. | UPB competitors |
| Greenwich Lifesciences Inc (GLSI) | Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /... | GLSI competitors |
| Shattuck Labs Inc (STTK) | Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. | STTK competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Atrium Therapeutics, Inc. Common Stock (RNA) | Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. | RNA competitors |
Frequently Asked Questions About SABS
Who are SAB Biotherapeutics' main competitors?
The companies most similar to SAB Biotherapeutics include Palisade Bio (PALI), Precision BioSciences (DTIL), Cartesian Therapeutics (RNAC), Q32 Bio (QTTB) and Invivyd (IVVD), listed from the closest match.
Who is SAB Biotherapeutics' biggest competitor?
Sana Biotechnology (SANA) is the largest of the similar companies at $605.26M; Palisade Bio (PALI) is the closest match by business profile, size, sector and industry.
How does SABS stock compare with its competitors?
SABS' net margin is 0.0% against a peer median of 0.0%.
Which of SAB Biotherapeutics' competitors pays a higher dividend?
SAB Biotherapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is SAB Biotherapeutics bigger than its competitors?
No. SAB Biotherapeutics is 5th by market cap among the 13 companies on this page; the largest is Sana Biotechnology (SANA) at $605.26M.
SABS pages: Overview, Earnings, Forecast, Financials, Competitors